bims-midomi Biomed News
on MDM2 and mitochondria
Issue of 2026–11–08
three papers selected by
Gavin McStay, Liverpool John Moores University



  1. Gynecol Oncol Rep. 2026 Dec;68 102238
      [Background] Low-grade endometrial stromal sarcoma (LG-ESS) generally follows an indolent clinical course, and high-grade transformation during disease progression is rare. [Case Presentation] We report a 44-year-old woman with Birt-Hogg-Dubé (BHD) syndrome who developed rapid transformation of LG-ESS to high-grade endometrial stromal sarcoma (HG-ESS). The patient underwent surgery for a presumed uterine leiomyoma and was diagnosed with FIGO stage IA LG-ESS. Six months after surgery, a vaginal cuff recurrence was detected and rapidly progressed despite letrozole treatment. Cytoreductive surgery was performed, and the recurrent tumor was diagnosed as HG-ESS. Re-review of the primary specimen revealed no high-grade component. Comprehensive genomic profiling of the recurrent tumor identified a ZC3H7B-BCOR fusion and MDM2 amplification, in addition to the germline pathogenic FLCN variant associated with BHD syndrome. Doxorubicin achieved a partial response, but the disease subsequently progressed during further treatment. This case demonstrates exceptionally rapid transformation from LG-ESS to BCOR-rearranged HG-ESS within 6 months. Although the temporal acquisition of the BCOR rearrangement could not be established because molecular testing was not performed on the primary tumor, the marked morphologic and clinical progression supports substantial tumor evolution. The identification of BCOR rearrangement and MDM2 amplification may provide insight into the aggressive clinical course. [Conclusions] This case highlights the potential value of comprehensive genomic profiling in recurrent ESS and suggests that MDM2 inhibitors may represent a future treatment strategy for selected patients.
    Keywords:  BCOR; Birt–Hogg–Dubé syndrome; Endometrial stromal sarcoma; FLCN; High-grade transformation; MDM2
    DOI:  https://doi.org/10.1016/j.gore.2026.102238
  2. Curr Top Med Chem. 2026 Oct 26.
       INTRODUCTION: An important regulatory aspect of cancer progression is the interaction between p53 and MDM2, particularly in breast cancer, where the excessive presence of MDM2 hampers p53's tumour- suppressing function. Although many natural flavonoids are recognized for their influence on this pathway, they often exhibit suboptimal potency and pharmacokinetic properties. To discover flavonoid derivatives with stronger inhibitory effects on the p53-MDM2 interaction, this research integrates Density Functional Theory (DFT), molecular docking, and AI-enhanced de novo optimization.
    MATERIALS AND METHODS: Validated molecular docking protocols were employed to evaluate 52 flavonoids from the Indonesian Natural Products Database against the p53-MDM2 complex, yielding a validation RMSD value of 0.4935 Å. AI-assisted molecular design was subsequently applied to the top-performing compounds to generate optimized derivatives with improved binding affinity and pharmacokinetic properties. Binding interactions were analyzed using conventional molecular visualization approaches. Drug-likeness, ADME, and toxicity profiles were predicted using SwissADME, ProTox-II, and ADMETlab 2.0. Density Functional Theory (DFT) calculations at the B3LYP/6-31G(d,p) level were performed to evaluate electronic properties and molecular stability. Furthermore, Molecular Dynamics (MD) simulations and MM-GBSA calculations were conducted to investigate the dynamic stability and binding free energy of the selected complexes.
    RESULTS: Among the AI-optimized derivatives, Amentoflavone-1 demonstrated the strongest binding affinity (-5.60 kcal/mol), outperforming Resveratrol (-4.24 kcal/mol). Interaction profiling revealed that hydrophobic interactions and π-π stacking with key residues within the p53-MDM2 binding pocket were the primary stabilizing forces. ADME predictions indicated improved drug-likeness and absorption properties, while toxicity analyses suggested reduced mutagenicity and mitochondrial toxicity, though a moderate hepatotoxicity risk remained. DFT calculations demonstrated favourable HOMO- LUMO energy gaps and frontier molecular orbital characteristics associated with molecular stability and chemical reactivity. Molecular dynamics simulations over 100 ns showed that the p53-MDM2- Amentoflavone-1 complex maintained a stable conformation comparable to the native ligand, as evidenced by RMSD, RMSF, SASA, and radius-of-gyration analyses. In addition, MM-GBSA calculations revealed a binding free energy of -18.37 kcal/mol for Amentoflavone-1, confirming spontaneous and thermodynamically favourable binding to the p53-MDM2 complex.
    DISCUSSION: The integration of AI-driven de novo design with conventional computational modelling successfully enhanced and clarified the pharmacological potential of flavonoid scaffolds. Amentoflavone- 1 exhibited favourable binding interactions consistent with known p53-MDM2 inhibition mechanisms, supported by stable molecular dynamics behaviour and thermodynamically favourable binding profiles. Improvements in ADME and toxicity parameters further suggest that AI-guided structural modification can effectively optimize flavonoid-based inhibitor candidates.
    CONCLUSION: Overall, AI-guided structural optimization improved the binding characteristics, molecular stability, and drug-likeness profile of Amentoflavone-1 relative to its parent compound. Although its binding affinity and MM-GBSA energy remained lower than those of the native ligand, Amentoflavone- 1 demonstrated stable interactions with the p53-MDM2 complex and should be considered a promising preliminary lead compound for further structural refinement and experimental validation.
    Keywords:  AI-driven drug design; de novo design; flavonoid derivatives; molecular docking; p53-MDM2 inhibition; triplenegative breast cancer (TNBC)
    DOI:  https://doi.org/10.2174/0115680266474465260825060836
  3. RSC Med Chem. 2026 Oct 27.
      Structure-guided grafting of cell-penetrating peptide (CPP) motifs into bioactive peptides can couple intracellular delivery with target recognition, but the chemistry of the grafted cationic residues may also reshape the bioactive conformation and trafficking behavior. Here, we examined the properties associated with global guanidinium-bearing residue substitutions within the p53-MDM2 inhibitor St3-R. All Arg residues in St3-R were replaced with homoarginine (St3-hR) or 2-amino-3-guanidinopropionic acid (St3-Agp), and the derivatives were evaluated by circular dichroism, molecular dynamics, surface plasmon resonance, flow cytometric analysis of cell-associated fluorescence under different temperature and inhibitor conditions, and live-cell NanoBRET. St3-hR showed a numerically higher α-helical content (40% versus 35%), a modestly lower mean MDM2 K D (K D = 104.3 ± 3.7 versus 113.8 ± 2.7 nM), similar cell-associated fluorescence of its FAM-labeled derivative, and a lower apparent NanoBRET IC50 (6.15 ± 0.06 versus 9.34 ± 0.54 μM) than St3-R. By contrast, St3-Agp displayed lower helicity, greater deviation from the starting structure, lower cell-associated fluorescence of its FAM-labeled derivative, and a higher apparent NanoBRET IC50 (17.90 ± 0.41 μM). At 4 °C, the cell-associated fluorescence of F-St3-Agp was 15.3% of its value at 37 °C, a larger relative fraction than for the other two labeled peptides; this does not establish direct membrane translocation or greater cytosolic delivery. Because St3-Agp was evaluated as an isomerically unresolved preparation, its properties cannot be attributed solely to side-chain shortening. Together, these findings highlight the importance of considering peptide conformation, target-binding affinity, and cellular behavior when optimizing guanidinium-bearing residues in CPP-grafted PPI inhibitors.
    DOI:  https://doi.org/10.1039/d6md00804f